PREPARATION OF HUMAN ALLOGENEIC LIVER-DERIVED PROGENITOR CELLS
The invention relates to a process for the manufacture of a population of human allogeneic liver-derived progenitor cells (HALPC). The process comprises the use of a xeno- and serum-free culture medium comprising purified native or recombinant human serum albumin.
1 . A process for the manufacture of a population of human allogeneic liver-derived progenitor cells (HALPC), comprising the steps of:
(a) providing a suspension of primary liver cells obtained from a human liver;
(b) culturing the primary liver cells comprised in said suspension under conditions that cause the emergence of a population of cells having an elongated shape and mesenchymal morphology;
(c) culturing the cell population emerged in step (b) under conditions that cause its expansion;
(d) harvesting the expanded cell population obtained in step (c);
wherein said cells of the expanded cell population obtained in step (c) are human allogeneic liver-derived progenitor cells (HALPC) that express at least one mesenchymal marker selected from CD90, CD44, CD73, CD13, CD140b, vimentin and alpha-smooth muscle actin (ASMA), and optionally express at least one hepatic marker and/or exhibit a liver-specific activity; and
wherein the culturing conditions of step (b) include the use of a xeno- and serum-free culture medium comprising purified native or recombinant human serum albumin.
2 . The process of claim 1 , wherein the xeno- and serum-free culture medium is further characterized in that it contains less than 30 ng/mL of epidermal growth factor (EGF).
3 . The process of claim 1 , further comprising a step of
(e) establishing that said cells of the expanded cell population obtained in step (c) are human allogeneic liver-derived progenitor cells (HALPC) that express at least one mesenchymal marker selected from CD90, CD44, CD73, CD13, CD140b, vimentin and alpha-smooth muscle actin (ASMA), and optionally express at least one hepatic marker and/or exhibit a liver-specific activity.
4 . The process of claim 1 , wherein the human allogeneic liver-derived progenitor cells obtained in step (c) or (d) express at least one mesenchymal marker selected from CD90, CD44, CD73, CD13, CD140b, CD29, vimentin and α-smooth muscle actin (ASMA); and secrete HGF.
5 . The process of claim 1 , wherein the human allogeneic liver-derived progenitor cells obtained in step (c) or (d) further secrete PGE2.
6 . The process of claim 1 , wherein the human allogeneic liver-derived progenitor cells obtained in step (c) or (d) are
(i) positive for α-smooth muscle actin (ASMA), CD140b and optionally albumin (ALB);
(ii) negative for Cytokeratin-19 (CK-19).
7 . The process of claim 1 , wherein the human allogeneic liver-derived progenitor cells obtained in step (c) or (d) are positive for CD90, CD73, vimentin and ASMA.
8 . The process of claim 1 , wherein the xeno- and serum-free culture medium comprises lipids, preferably selected from one or more fatty acids, and wherein the lipids are associated with or bound to the purified native or recombinant human serum albumin.
9 . The process of claim 1 , wherein the xeno- and serum-free culture medium comprises:
(i) a purified native or recombinant human transferrin, and wherein the human transferrin has optionally been pre-treated with an iron compound;
(ii) recombinant human insulin; and
(iii) a selenium compound, such as sodium selenite.
10 . The process of claim 1 , wherein the xeno- and serum-free culture medium comprises basic fibroblast growth factor (FGF2) at a level of 30 pg/mL or higher, and optionally acidic fibroblast growth factor (FGF1) at a level of 5 pg/mL or higher.
11 . The process of claim 1 , wherein the xeno- and serum-free culture medium comprises human fibronectin and/or human vitronectin, such as recombinant human fibronectin and/or recombinant human vitronectin.
12 . The process of claim 1 , wherein the xeno- and serum-free culture medium comprises glucose, and wherein the glucose content is not higher than about 2.5 wt.-%, and optionally not higher than about 1 wt.-%.
13 . The process of claim 1 , wherein the xeno- and serum-free culture medium comprises glutamine or a salt thereof, or a compound capable of releasing glutamine or a salt thereof.
14 . The process of claim 1 , wherein the xeno- and serum-free culture medium comprises:
(iv) inorganic salts, including salts of calcium, iron (II), iron (III), potassium, copper (II), magnesium, sodium, and zinc;
(v) amino acids, including L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-cystine, L-glutamine, L-glutamic acid, glycine, L-histidine, L-isoleucine, L-leucine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine;
(vi) vitamins, including D(+)-biotin, D-calcium pantothenate, choline chloride, folic acid, myo-inositol, nicotinamide, pyridoxal, pyridoxine, riboflavin, thiamine, and vitamin B12; and optionally
(vii) DL-thioctic acid, hypoxanthine, linoleic acid, phenol red sodium, putrescine, pyruvate, and/or thymidine; and
wherein the pH of the culture medium is adjusted to pH 6.9-7.5.
15 . The process of claim 1 , wherein the culturing conditions of step (c) include the use of a xeno- and serum-free culture medium comprising purified native or recombinant human serum albumin, and wherein the xeno- and serum-free culture medium used in step (c) is further characterized in that it comprises no EGF.
16 . The process of claim 1 , wherein the xeno- and serum-free culture medium used in step (c) is further characterized in that it comprises (i) a purified native or recombinant human transferrin, and wherein the human transferrin has optionally been pre-treated with an iron compound;
(ii) recombinant human insulin; and
(iii) a selenium compound, such as sodium selenite.
17 . The process of claim 1 , wherein step (c) comprises passaging the cell population emerged in step (b) at least twice.
18 . The process of claim 1 , further comprising the steps of
(c1) harvesting the cell population obtained in step (b) or after any passage of step (c);
(c2) adding a cryoprotectant to the cell population harvested in step (c1) to obtain a cryoprotected cell formulation;
(c3) freezing said cryoprotected cell formulation; and
(c4) thawing said frozen cryoprotected cell formulation;
wherein steps (c1) to (c4) are performed as sub-steps of step (c).
19 . The use of a xeno- and serum-free culture medium comprising purified native or recombinant human serum albumin for culturing primary liver cells obtained from a human liver such as to produce human allogeneic liver-derived cells.
20 . The use of a xeno- and serum-free culture medium according to claim 19 , wherein the medium is further characterized in that it contains less than 30 ng/mL of epidermal growth factor (EGF).
21 . The use of a xeno- and serum-free culture medium according to claim 19 , wherein the xeno- and serum-free culture medium further comprises lipids, preferably selected from one or more fatty acids, and wherein the lipids are associated with or bound to the purified native or recombinant human serum albumin.
22 . The use of a xeno- and serum-free culture medium according to claim 19 , wherein the xeno- and serum-free culture medium comprises:
(i) a purified native or recombinant human transferrin, and wherein the human transferrin has optionally been pre-treated with an iron compound;
(ii) recombinant human insulin; and
(iii) a selenium compound, such as sodium selenite.
23 . The use of a xeno- and serum-free culture medium according to claim 19 , wherein the xeno- and serum-free culture medium comprises basic fibroblast growth factor (FGF2) at a level of 30 pg/mL or higher, and optionally acidic fibroblast growth factor (FGF1) at a level of 5 pg/mL or higher.
24 . The use of a xeno- and serum-free culture medium according to claim 19 , wherein the xeno- and serum-free culture medium comprises human fibronectin and/or human vitronectin, such as recombinant human fibronectin and/or recombinant human vitronectin.
25 . The use of a xeno- and serum-free culture medium according to claim 19 , wherein the xeno- and serum-free culture medium comprises glucose, and wherein the glucose content is not higher than about 2.5 wt.-%, and optionally not higher than about 1 wt.-%.
26 . The use of a xeno- and serum-free culture medium according to claim 19 , wherein the xeno- and serum-free culture medium comprises glutamine or a salt thereof, or a compound capable of releasing glutamine or a salt thereof.
27 . The use of a xeno- and serum-free culture medium according to claim 19 , wherein the xeno- and serum-free culture medium comprises:
(iv) inorganic salts, including salts of calcium, iron (II), iron (III), potassium, copper (II), magnesium, sodium, and zinc;
(v) amino acids, including L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-cystine, L-glutamine, L-glutamic acid, glycine, L-histidine, L-isoleucine, L-leucine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine;
(vi) vitamins, including D(+)-biotin, D-calcium pantothenate, choline chloride, folic acid, myo-inositol, nicotinamide, pyridoxal, pyridoxine, riboflavin, thiamine, and vitamin B12; and optionally
(vii) DL-thioctic acid, hypoxanthine, linoleic acid, phenol red sodium, putrescine, pyruvate, and/or thymidine; and
wherein the pH of the culture medium is adjusted to pH 6.9-7.5.
28 . The use of a xeno- and serum-free culture medium according to claim 19 , wherein the xeno- and serum-free culture medium comprises no EGF.
29 . An isolated population of human allogeneic liver-derived progenitor cells that are positive for CD90, CD73, vimentin and ASMA; and that exhibit in average less than 2.5% clonal aberrations per metaphase and/or less than 15% non-clonal aberrations per metaphase.
30 . The isolated population of human allogeneic liver-derived progenitor cells according to claim 29 for use in the treatment of a liver disease.
31 . A cryoprotected cell formulation comprising the isolated population of human allogeneic liver-derived progenitor cells according to claim 29 and one or more cryoprotectants, wherein the cryoprotected cell formulation is optionally frozen.